Fc receptors play a central role in the immune system where they control the extent and strength of an immune response. Based on these proteins SuppreMol is developing novel concepts for the treatment of autoimmune diseases. The most advanced product is SM101, a soluble Fc gamma receptor IIB
(sFcγRIIB), which competes with FcγRs expressed on immune cells for pathogenic immune complexes. Interference at this early stage of the immune reaction prevents the triggering of the cascade that results in inflammation and tissue destruction.
SuppreMol’s treatment approach has the potential to specifically rebalance the impaired immune functions of the immune system rather than just treating the disease symptoms. Data suggest that SM101 also accumulates in lymphoid tissue. In addition to immune complex competition SM101 interferes with the formation of memory/plasma cells that are causative for the formation of new pathogenic antibodies. This dual mode of action may allow the treatment of different autoimmune diseases.
SuppreMol is also developing several antibody candidates that either target specific subtypes of
Fc receptors or IL-3 for the treatment of further autoimmune diseases and allergies. See: SM201; SM301; SM401.